//
//  fda.swift
//  aOncology
//
//  Created by Philippe-Faurie on 5/15/18.
//  Copyright © 2018 Philippe-Faurie. All rights reserved.
//

import Foundation
/*
var approvedCombo : [String: [String: Int]] =

"abarelix" : "prostate cancer"

abemaciclib + fulvestrant : breast
abiraterone : CRPC or CSPC ( castration-resistant prostate cancer, castration-sensitive prostate cancer)
adalimumab
ado-trastuzumab emtansine : breast : HER2-positive
afatinib : NSCLC : EGFR
alectinib :NSCLC : ALK-positive
asparaginase: ALL
atezolizumab: urothelial carcinoma, NSCLC
avelumab: urothelial carcinoma , Merkel cell carcinoma (MCC)
axitinib: renal cell carcinoma
belinostat: peripheral T-cell lymphoma (PTCL)
bevacizumab + irinotecan : colorectal, glioblastoma
bevacizumab + topotecan : servical
bexarotene : T-cell lymphoma
bicalutamide : prostate
bleomycin : Squamous Cell Carcinoma, Hodgkin’s disease, non-Hodgkin’s lymphoma, Testicular Carcinoma, Malignant Pleural Effusion

blinatumomab: ALL
bortezomib: multiple myeloma, mantle cell lymphoma
bosutinib: CML
brentuximab vedotin: Hodgkin lymphoma, systemic anaplastic large cell lymphoma
brigatinib: NSCLC
cabozantinib: advanced renal cell carcinoma (RCC)
carfilzomib + lenalidomide + dexamethasone: multiple myeloma
carmustine: Brain tumors glioblastoma, brainstem glioma, medulloblastoma,
astrocytoma, ependymoma, and metastatic brain tumors, Hodgkin's lymphoma
carmustine + prednisone : multiple myeloma
ceritinib : NSCLC : ALK
cetuximab + platinum : Head and Neck
cetuximab + folfiri  : Colorectal
cetuximab +irinotecan             : Colorectal
clofarabine: ALL 1-21 yo
cobimetinib + vemurafenib: melanoma : BRAF V600E, BRAF V600K
copanlisib : follicular lymphoma (FL)
crizotinib : NSCLC : ALK + ROS1-positive
dabrafenib :melanoma , NSCLC , anaplastic thyroid cancer (ATC) : BRAF V600E
daratumumab + bortezomib, melphalan and prednisone : multiple myeloma
dasatinib : Philadelphia chromosome-positive (Ph+) (CML), Ph+ ALL
degarelix : Prostate
durvalumab : NSCLG,  urothelial carcinoma, PD-L1
enasidenib : AML
enzalutamide : castration-resistant prostate cancer
eribulin : breast, liposarcoma
erlotinib : NSCLC
*/



